- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07660913
Effectiveness of Matrix Rhythm Therapy on Carpal Tunnel Syndrome
7. juli 2026 oppdatert av: Ertan Şahinoğlu, PhD, Izmir Bakircay University
Effectiveness of Matrix Rhythm Therapy on Symptom Severity and Function in Carpal Tunnel Syndrome: A Randomized, Placebo-Controlled, Assessor-Blinded Trial
The purpose of this study is to investigate the effects of matrix rhythm therapy, applied in addition to conventional treatment, on symptom severity, function, grip and pinch strength, and quality of life in patients with carpal tunnel syndrome.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
84
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Ertan Şahinoğlu, PhD
- Telefonnummer: 14101 +90 232 493 00 00
- E-post: ertan.sahinoglu@bakircay.edu.tr
Studer Kontakt Backup
- Navn: Ayşe Kayalı Vatansever, PhD
- Telefonnummer: 14046 +90 232 493 00 00
- E-post: ayse.vatansever@bakircay.edu.tr
Studiesteder
-
-
-
Izmir, Tyrkia (Türkiye), 35665
- Rekruttering
- Izmir Bakircay University
-
Ta kontakt med:
- Bülent Toğram
- Telefonnummer: +90 232 493 00 00
- E-post: sbf@bakircay.edu.tr
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Having a diagnosis of unilateral carpal tunnel syndrome confirmed by an orthopedist based on clinical examination and electromyography (EMG) testing.
- Being classified with mild-to-moderate carpal tunnel syndrome severity.
- Having symptoms persisting for at least 12 weeks.
- Having a Mini-Mental State Examination (MMSE) score greater than 24.
- Being literate (able to read and write).
Exclusion Criteria:
- History of prior carpal tunnel release surgery.
- History of corticosteroid injection into the affected hand/wrist.
- Having received physiotherapy for carpal tunnel syndrome within the last 6 months.
- Presence of any neurological signs or symptoms in the upper extremity other than carpal tunnel syndrome.
- History of prior surgery in the hand or wrist region due to other conditions.
- Diagnosis of any systemic neurological disease.
- Diagnosis of rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Having ongoing pain in the arm or hand due to any other underlying cause.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Matrix Rhythm Therapy Group
This group will receive a conventional physiotherapy treatment combined with active matrix rhythm therapy.
|
Active matrix rhythm therapy applied for 40 minutes per session (10 min paraspinal muscles, 10 min over the flexor retinaculum, 10 min to extensor muscles, and 10 min to flexor muscles), 2 sessions per week for 6 weeks.
Participants use a night splint holding the wrist in neutral position.
On clinic days, conservative physiotherapy sessions are administered immediately following the active or sham matrix rhythm therapy sessions, 2 days per week for 6 weeks.
These supervised sessions include median nerve sliding exercises (3 sets, 5 reps) and passive stretching for wrist flexors/extensors (15-sec hold, 3 sets, 5 reps).
In addition to clinical sessions, the same exercise protocol is performed at home twice daily and continued independently up to the 12th-week follow-up.
Compliance with both splint wear and home exercises is strictly monitored using participant usage logs and exercise diaries.
|
|
Sham-komparator: Sham Matrix Rhythm Therapy Group
This group will receive a conventional physiotherapy treatment combined with a placebo application using the Hypervolt 2 Pro device.
|
Participants use a night splint holding the wrist in neutral position.
On clinic days, conservative physiotherapy sessions are administered immediately following the active or sham matrix rhythm therapy sessions, 2 days per week for 6 weeks.
These supervised sessions include median nerve sliding exercises (3 sets, 5 reps) and passive stretching for wrist flexors/extensors (15-sec hold, 3 sets, 5 reps).
In addition to clinical sessions, the same exercise protocol is performed at home twice daily and continued independently up to the 12th-week follow-up.
Compliance with both splint wear and home exercises is strictly monitored using participant usage logs and exercise diaries.
Placebo application using the Hypervolt 2 Pro device for 40 minutes per session (10 min paraspinal, 10 min flexor retinaculum, 10 min extensors, 10 min flexors), 2 sessions per week for 6 weeks.
It mimics the physical vibration and head shape of the matrix rhythm therapy device to maintain blinding.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in the Boston Carpal Tunnel Questionnaire - Symptom Severity Scale at 6 and 12 Weeks
Tidsramme: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
This scale evaluates the severity of symptoms including pain, numbness, and paresthesia over the past two weeks.
It consists of 11 items, each scored on a Likert scale from 1 (no symptoms) to 5 (most severe symptoms).
The total score is calculated by dividing the sum of individual item scores by 11.
Final scores range from 1 to 5, where higher scores indicate greater symptom severity.
|
Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
|
Change from Baseline in the Boston Carpal Tunnel Questionnaire - Functional Status Scale at 6 and 12 Weeks
Tidsramme: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
This scale assesses hand-related functional limitations during daily activities.
It consists of 8 items, each scored on a Likert scale from 1 (no difficulty) to 5 (cannot perform activity at all).
The total score is calculated by dividing the sum of individual item scores by 8. Final scores range from 1 to 5, where higher scores indicate greater functional impairment.
|
Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Hand Grip Strength at 6 and 12 Weeks
Tidsramme: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
Measured using a hand dynamometer.
The participant is seated with the shoulder adducted at 0 degrees, elbow flexed at 90 degrees, and forearm/wrist in neutral position.
The measurement will be repeated three times for the affected hand with 5-second intervals, and the arithmetic mean will be recorded.
Higher values indicate greater grip strength measured in kilograms (kg).
|
Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
|
Change from Baseline in Pinch Strength at 6 and 12 Weeks
Tidsramme: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
Assessed using a pinch gauge to measure tip pinch strength.
The participant is seated with the shoulder adducted at 0 degrees, elbow flexed at 90 degrees, and forearm/wrist in neutral position, and asked to squeeze the device with maximum effort using the tips of the thumb and index finger.
The measurement will be repeated three times for the affected hand with 5-second intervals, and the arithmetic mean will be recorded.
Higher values indicate greater pinch strength measured in kilograms (kg).
|
Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
|
Change from Baseline in the EQ-5D-5L Index Score at 6 and 12 Weeks
Tidsramme: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
Evaluated using the EuroQol (EQ-5D-5L) scale, which covers 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has 5 response levels.
These responses are converted into a single health-state index score using the country-specific value set.
Index scores typically range from less than 0 to 1, where higher scores indicate a better health-related quality of life.
|
Baseline, Post-treatment (Week 6), and Follow-up (Week 12)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juli 2026
Primær fullføring (Antatt)
1. juli 2027
Studiet fullført (Antatt)
1. september 2027
Datoer for studieregistrering
Først innsendt
16. juni 2026
Først innsendt som oppfylte QC-kriteriene
16. juni 2026
Først lagt ut (Faktiske)
22. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
8. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2963
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .